Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Techknow Invest Roadshow Webinar (May 2020)

21 slides from Neuroscientific Biopharmaceuticals's conference presentation, May 20, 2020

  1. Slide 1: NeuroScientific to Present at TechKnow Invest Roadshow Webinar

    For personal use only ASX ANNOUNCEMENT NeuroScientific to Present at TechKnow Invest Roadshow Webinar Perth, Australia; 20 May 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB (“NeuroScientific” or ”the Company”) is pleased to advise shareholders and investors that NeuroScientific CEO and Manag

  2. Slide 2: Novel Drug Therapies for Neurodegenerative Conditions

    For personal use only NOVEL DRUG T H E R A P IE S F O R N E U R O D E G E N E R A T IV E C O N D IT IO N S

  3. Slide 3: Disclaimer

    DISCLAIMER The purpose of the presentation is to provide an update of the business of For personal use only NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  4. Slide 4: Corporate Overview

    CORPORATE OVERVIEW For personal use only • Completed IPO listing on the ASX July 2018 • Lead candidate funded through to completion of Phase I • Pipeline of potential therapeutic candidates with strong IP protection ASX code NSB Shares on issue 78.38M Price (close 19/05/2020) $0.185 Market cap $14M

  5. Slide 5: Company Highlights

    COMPANY HIGHLIGHTS For personal use only Advanced preclinical lead drug candidate with multiple treatment indications Strong strategic partnerships geared towards success Validated strategy and business model Experienced board and management team

  6. Slide 6: Leadership Team

    LEADERSHIP TEAM For personal use only , MBA Co-founder of ResApp Health 13+ years experience Founding director of 20 years’ experience in Ltd (ASX.RAP), Imugene Ltd commercialising medical Actinogen Medical corporate advisory and (ASX:IMU) and Oncosil Ltd devices and pharmaceuticals (ASX:ACW) an adv

  7. Slide 7: Treatment Markets with Unmet Need

    TREATMENT MARKETS WITH UNMET NEED For personal use only ALZHEIMER’S DISEASE OPTIC NERVE CONDITIONS 48M people globally 5% of population have dementia suffer vision loss due to 70% of dementias damaged optic nerve Alzheimer’s disease 60M people US $818B global affected by Glaucoma economic burden US$

  8. Slide 8: Lead Candidate: EmtinB

    LEAD CANDIDATE: EMTINB For personal use only NOVEL • Modeled on Metallothionein (MT-II) - a well known neuroprotective and neurogenerative compound, with EmtinB showing superior drug properties • Binds LRP-1 receptors – novel Mechanism of Action (MOA) • Stops cell death & stimulates regeneration VAL

  9. Slide 9: Evolution of EmtinB

    EVOLUTION OF EMTINB For personal use only MT-II STRUCTURE EmtinB Peptide EmtinB Peptide Dendrimer β-domain α-domain • 61 amino acid length • 14 amino acid length • Synthesised as a tetrameric • Binds divalent metal ions • Isolated from the β-domain of dendrimer • Difficult to manufacture MT-II prote

  10. Slide 10: Scientific Data: Preclinical Survival

    EMTINB SCIENTIFIC DATA P re c lin ic a l s u rviva l For personal use only CO RTEX HIP P O CAMP US HIP P O CAMP US: ALZHEIMER’S MO DEL 10

  11. Slide 11: Scientific Data: Preclinical Regeneration

    EMTINB SCIENTIFIC DATA P re c lin ic a l re g e n e ra t io n For personal use only CO RTEX HIP P O CAMP US HIP P O CAMP US: INJ URY MO DEL SP INAL CO RD: INJ URY MO DEL 11

  12. Slide 12: Scientific Data: Spinal Cord Injury Model

    EMTINB SCIENTIFIC DATA Spinal cord injury model • For personal use only Primary neurons isolated from spinal cord tissue of adult rats • EmtinB (30µg/mL) neuron regeneration >300% vs. untreated control • EmtinB (30µg/mL) neuron regeneration >2x Copaxon®; marketed drug for Multiple Sclerosis • EmtinB

  13. Slide 13: Scientific Data: Multiple Sclerosis Remyelination Model

    EMTINB SCIENTIFIC DATA Mu lt ip le s c le ro s is re m ye lin a t io n m o d e l • For personal use only EmtinB had a significant positive effect on the proliferation and differentiation of oligodendrocytes, indicating a very significant effect on remyelination • EmtinB significantly increased the n

  14. Slide 14: Scientific Data: Preclinical Studies Animal Models

    EMTINB SCIENTIFIC DATA P re c lin ic a l s t u d ie s : a n im a l m o d e ls For personal use only • Crosses the blood brain barrier • Slowed progression of disease (memory impairment) by >80% in Alzheimer’s animal model Cognition: treatment for 48 days EmtinB 70% +7 Control 38% +5 0% 50% 100%

  15. Slide 15: Supporting Scientific Data: Regenerating the Optic Nerve

    SUPPORTING SCIENTIFIC DATA Regenerating the optic nerve For personal use only • Precursor to EmtinB (MT-II) stimulated regenerative growth of optic • Promotes axonal regeneration through an inhibitory environment in vivo Optic Nerve Growth No Treatment Treatment

  16. Slide 16: Ocular Data: Neuroprotection and Regeneration of the Optic Nerve

    EMTINB OCULAR DATA Neuroprotection and regeneration of the optic nerve For personal use only • Labeled EmtinB significantly penetrated the retina and optic nerve of the rabbit eye with no side effects • Significant concentrations of EmtinB detected at 3-h, 6-h, and 9-h • EmtinB passed through the oc

  17. Slide 17: Ocular Data: Neuroprotection in Glaucoma Pig Model

    EMTINB OCULAR DATA Neuroprotection and regeneration of the optic nerve For personal use only • EmtinB demonstrated neuroprotection in glaucoma pig model • High intraocular pressure pig model is the closest experiment to replicate severe human glaucoma pathology; positive results in this model indica

  18. Slide 18: Development Schedule

    EMTINB DEVELOPMENT SCHEDULE For personal use only 2020 2020 2020 2020 2021 2021 2021 2021 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Neurodegenerative indications Complete preclinical safety & No toxicity in dose levels 60x toxicology studies higher than planned clinical dose Complete GMP manufacturing Assuming no fur

  19. Slide 19: Strategic Partnerships

    STRATEGIC PARTNERSHIPS Research Partners Manufacturing Partners For personal use only 19

  20. Slide 20: Business Model

    BUSINESS MODEL • Company will seek to out-license EmtinB for late-stage clinical development For personal use only • Potential for multiple treatment indications will be attractive to “big pharma” 20

  21. Slide 21: Novel Drug Therapies for Neurodegenerative Conditions

    For personal use only NOVEL DRUG T H E R A P IE S F O R N E U R O D E G E N E R A T IV E C O N D IT IO N S

NeuroScientific Biopharmaceuticals — Techknow Invest Roadshow Webinar (May 2020) on 6ix